|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-6-28
|
|
pubmed:abstractText |
To study whether modification of LDL by methylglyoxal (MG), a potent arginine-directed glycating agent that is increased in diabetes, is associated with increased atherogenicity.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1939-327X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
© 2011 by the American Diabetes Association.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1973-80
|
|
pubmed:meshHeading |
pubmed-meshheading:21617182-Animals,
pubmed-meshheading:21617182-Aorta,
pubmed-meshheading:21617182-Apolipoprotein B-100,
pubmed-meshheading:21617182-Apolipoproteins E,
pubmed-meshheading:21617182-Atherosclerosis,
pubmed-meshheading:21617182-Cardiovascular Diseases,
pubmed-meshheading:21617182-Cholesterol, LDL,
pubmed-meshheading:21617182-Glycosylation,
pubmed-meshheading:21617182-Hep G2 Cells,
pubmed-meshheading:21617182-Humans,
pubmed-meshheading:21617182-Mice,
pubmed-meshheading:21617182-Particle Size,
pubmed-meshheading:21617182-Proteoglycans,
pubmed-meshheading:21617182-Pyruvaldehyde,
pubmed-meshheading:21617182-Rats,
pubmed-meshheading:21617182-Receptors, LDL
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes.
|
|
pubmed:affiliation |
Warwick Medical School, Clinical Sciences Research Institute, University of Warwick, University Hospital, Coventry, UK. n.rabbani@warwick.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
